Linaglitpin Intas

Linagliptin, the active ingredient in Linaglitpin Intas, is a Dipeptidyl peptidase-4 (DPP-4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Linaglitpin Intas as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder affecting glucose regulation. - Type 2 diabetes mellitus: improves glycaemic control when used as monotherapy. - Type 2 diabetes mellitus combined with metformin: provides additional HbA1c reduction. - Type 2 diabetes mellitus with lifestyle therapy: assists patients in achieving target blood‑glucose levels alongside diet and exercise.

Adverse reactions may occur with linagliptin therapy.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory infection symptoms. - Headache: transient cranial discomfort. - Upper respiratory tract infection: cough, sore throat, or congestion. - Dizziness: occasional light‑headedness. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhoea. - Back pain: musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: angioedema, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. - Hepatic injury: elevated liver enzymes or jaundice. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Bullous pemphigoid: rare autoimmune skin disorder.

Before initiating linagliptin, consider the following precautions. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: use with caution in patients with liver disease. - Risk of hypoglycaemia: avoid dose‑related hypoglycaemia when combined with insulin or sulfonylureas. - History of pancreatitis: discontinue if signs of pancreatitis develop. - Pregnancy and lactation: consult prescriber; safety data are limited. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Insulin: may increase risk of severe hypoglycaemia. - Sulfonylureas: combined use can potentiate hypoglycaemic episodes. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin efficacy by inducing metabolism. - Diuretics: can affect glucose control; monitor blood sugar. - ACE inhibitors: observe renal function and electrolytes during co‑administration.